The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
about
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioAllogeneic transplantation for chronic lymphocytic leukemiaA prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignanciesCytomegalovirus in hematopoietic stem cell transplant recipientsExperience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying DiseaseA comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants.Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.Acute graft-versus-host disease: new treatment strategies.Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current statusPredictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations.In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies.Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
P2860
Q34044024-821774B6-4404-4FF5-96F7-E705702A5564Q34202277-33F8A0D9-2A23-42B8-9A07-71AA771B8E6EQ34549313-90ADC8CE-C111-49B5-96BA-32F7721F7D69Q35213027-BE4F26D5-C7DE-4119-AF43-304C15D443E5Q35922928-A447AE59-E93B-48EE-90AA-34AA42C2F6BEQ36156205-71D530DE-14DB-40F6-8E5A-9C9C13AD2498Q36532550-98433867-5C10-4FE4-A347-03569F3B7D1DQ37161367-D69994DD-D34A-4E0D-8355-460CB1828E09Q37610714-BF9F7C26-459C-4AA9-832E-1DCEB9518767Q37832506-D3734D0E-570E-4BE7-8065-9134BA591D7CQ38108320-FC221500-2017-4E4C-8562-6F30A7190357Q38311900-C16F4A1D-4774-42FB-9430-30ECA3E667F0Q39459351-15AA46EE-2AF8-4FF3-8619-D66436BDB153Q44477117-34C7A226-957D-4081-A6A3-33CE6ECAB060Q47572547-C1A3A6E2-725B-4F25-8C1E-831D3DB557CAQ50268592-DC32264C-A547-440C-8C66-A0538169295AQ50984719-D6B79E3D-59EE-4D84-A764-E6F9B70AED40Q56461161-7DCFD005-BCB0-4314-95DC-309FF95FF90C
P2860
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@en
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@nl
type
label
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@en
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@nl
prefLabel
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@en
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@nl
P2093
P1476
The effect of in vivo T cell d ...... chronic lymphocytic leukemia.
@en
P2093
Amit Nathwani
Anna Sureda
Dolores Caballero
Donald Milligan
Jorge Sierra
Jose A Perez-Simon
Karl Peggs
Kirsty Thomson
Lourdes Vazquez
Panagiotis Kottaridis
P304
P356
10.1016/J.BBMT.2008.09.001
P577
2008-11-01T00:00:00Z